Related Experiment Video
Updated: Jan 15, 2026
Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
Positive Immunoreactivities of TM9SF1 and EBAG9 are Associated With Poor Prognosis in Patients With Triple-Negative
Keiichi Kinowaki1, Toshihiko Takeiwa2, Kazuhiro Ikeda3
1Department of Pathology, Toranomon Hospital, Tokyo, Japan; Okinaka Memorial Institute for Medical Research, Tokyo, Japan.
Introduction:
TNBC demonstrates poor prognosis compared to other breast cancer types due to the lack of targetable molecular markers. Protein expression of EBAG9 has been associated with unfavorable prognosis in patients with various malignancies. Recently, we identified TM9SF1 protein as a binding partner for EBAG9 protein. However, the clinical relevance of TM9SF1 and EBAG9 in TNBC remains unclear.
Patients And Methods:
We investigated the clinicopathological significance of TM9SF1 and EBAG9 in 116 Japanese female TNBC patients using immunohistochemical analysis.
Results:
Immunohistochemical analysis demonstrated that IRs of both TM9SF1 and EBAG9 were significantly associated with decreased distant disease-free survival and overall survival. TM9SF1 IR was positively correlated with EBAG9 IR. These findings suggest that both TM9SF1 and EBAG9 IRs represent promising prognostic markers in TNBC.
